News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
AstraZeneca PLC Pipeline Holed As Phase 3 Diabetes Drug Fails
May 4, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, May 4 (Reuters) - AstraZeneca Plc's already weak pipeline of new drugs suffered a fresh setback on Thursday when it scrapped development of late-stage diabetes drug Galida, sending its shares 1.3 percent lower.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Europe
AstraZeneca
MORE ON THIS TOPIC
Neuropsychiatric disorders
Vistagen in freefall as social anxiety drug fails Phase 3
July 1, 2026
·
2 min read
·
Tristan Manalac
Podcast
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
July 1, 2026
·
2 min read
·
Jef Akst
Insights
Golden Triangle still dominates, but talent and capital gaps slow biotech growth
July 1, 2026
·
3 min read
·
Jennifer C. Smith-Parker
Job Trends
Opinion: Innovation wins the contract. Complexity loses the renewal
July 1, 2026
·
3 min read
·
Antonio Serrano
